{"doi":"10.1111/pcmr.13109","title":"Neutrophil‐to‐eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with <scp>anti‐PD</scp>‐1 therapy","abstract":"Neutrophil-to-lymphocyte ratios (NLR) and eosinophil counts are associated with improved survival in melanoma patients treated with immune checkpoint inhibitors, but no study has investigated neutrophil-to-eosinophil ratios (NER) as a predictive indicator in this population. In this retrospective study evaluating anti-PD-1 treated patients with advanced melanoma, progression-free survival (PFS), overall survival (OS), objective response rates (ORR), and risk of high-grade (grade ≥3) immune-related adverse events (irAEs) were compared between groups defined by median pretreatment NLR and NER as well as median NLR and NER at 1-month post-treatment. Lower baseline NLR and NER were associated with improved OS [HR: 0.504, 95% CI: 0.328-0.773, p = .002 and HR: 0.442, 95% CI: 0.288-0.681, p < .001, respectively] on univariate testing. After accounting for multiple covariates, our multivariate analysis found that lower pretreatment NER was associated with better ORR (by irRECIST) (OR: 2.199, 95% CI: 1.071-4.582, p = .033) and improved OS (HR: 0.480, 95% CI: 0.296-0.777, p = .003). Baseline NLR, 1-month NLR, and 1-month NER were not associated with ORR, PFS, or OS outcomes; but 1-month NER correlated with lower risk of grade ≥3 irAEs (OR: 0.392, 95% CI: 0.165-0.895, p = .029). Our findings suggest baseline NER merits additional investigation as a novel prognostic marker for advanced melanoma patients receiving anti-PD-1-based regimens.","journal":"Pigment Cell & Melanoma Research","year":2023,"id":332843,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":24,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9586,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":510333,"name":"Yeonhee Park","orcid":"0000-0001-9645-3407","position":1,"is_corresponding":false},{"id":1060006,"name":"Yusuf M. Mohamoud","orcid":null,"position":2,"is_corresponding":false},{"id":405631,"name":"Dahlia Tesfamichael","orcid":null,"position":3,"is_corresponding":false},{"id":366105,"name":"Hamid Emamekhoo","orcid":"0000-0002-8506-8703","position":4,"is_corresponding":false},{"id":293198,"name":"Alexander Birbrair","orcid":"0000-0003-1015-2561","position":5,"is_corresponding":false},{"id":471863,"name":"Mark R. Albertini","orcid":"0000-0002-6499-517X","position":6,"is_corresponding":false},{"id":614807,"name":"T. Vincent","orcid":"0000-0002-8417-2787","position":7,"is_corresponding":false},{"id":1059497,"name":"Vincent Pozorski","orcid":"0000-0002-4597-0794","position":0,"is_corresponding":true}],"reference_count":18,"raw_metadata":null,"created_at":"2026-07-19T01:09:35.125543Z","pmid":"37903733","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}